Developer docs
API playgroundTry for free, no card

Search company profiles

cellArtgen

Full company profile

uuid000evjf

Namestring
cellArtgen
Legal namestring
주식회사 세라트젠
Websiteurl
cellartgen.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

CellArtgen (주식회사 세라트젠) is a Seoul-based regenerative medicine biotechnology company founded in 2020 as a spin-off from Yonsei University, specializing in the convergence of organoid technology and functional biomaterials. The company develops three core technology platforms: organoid culture and manufacturing technology, organoid advancement/analytical technology (including molecular, electrical, structural, imaging, and AI-based analysis), and engraftable biomaterial technology. Its commercial portfolio centers on the Regenix® platform — decellularized organoid culture materials available across nine organ types (liver, intestine, lung, heart, kidney, uterus, muscle, skin, and xenograft) — and ORGANOSCREEN, a preclinical drug evaluation service using organoid-based disease models for conditions including MASH (liver), IPF (lung), sarcopenia (muscle), and cardiac safety assessment. CellArtgen claims to be Korea's first provider of liver organoid-based MASH and lung organoid-based IPF drug evaluation services.

The company operates a horizontally diversified business model across B2B pharmaceutical services, B2B research product sales, and consumer aesthetics. Revenue is generated through four streams: (1) ORGANOSCREEN preclinical evaluation services sold to domestic and global pharmaceutical companies and CROs, (2) Regenix product sales to research institutions, (3) medical biomaterial products co-developed with partners such as MonetCell for tissue regeneration, and (4) Cellumé, an ECM-based dermocosmetic skincare brand distributed through GS Home Shopping and live commerce channels (including Japan TikTok Shop). The organization has 11-50 employees, holds approximately 90+ domestic and international patents, and reports GMP certification obtained in January 2026 for wound coverage materials. Key academic partnerships include Yonsei University, Sungkyunkwan University, iPS Academia Japan, and the Korea Brain Research Institute, with strategic biotech collaborations including ToolGen, Kangstem, Mepsgen, and Woongbi Meditech.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organoid technology platforms, regenerative medicine solutions, preclinical drug evaluation, biomaterial products, tissue engineering research
Industry1 code
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Drug Evaluation Services (ORGANOSCREEN)
TypeProfessional Services
Description

Preclinical evaluation services using organoid-based disease models for pharmaceutical companies. Services include efficacy and safety assessment for drug candidates using liver, lung, muscle, and heart organoids.

cellartgen.com
2Regenix Product Sales
TypeOne Time License
Description

Sale of cell culture materials branded as Regenix for various organoid types (Liver, Intestine, Lung, Heart, Kidney, Uterus, Muscle, Skin, Xenograft).

cellartgen.com
3Biomaterial Products
TypeOne Time License
Description

Medical biomaterials including decellularized ECM products for tissue regeneration and aesthetic applications.

cellartgen.com
4Cellumed Skincare
TypeHardware Sales
Description

ECM-based skincare products (Cellumed brand) sold through GS Home Shopping and live commerce channels.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Regenix product catalog with various organoid types
ModelOtherBilling cadencePay-as-you-go
Notes

Products available include Regenix Liver, Intestine, Lung, Heart, Kidney, Uterus, Muscle, Skin, Xenograft. Forms available as Pre-gel Solution and Powder. Pricing requires direct inquiry.

cellartgen.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Cellumé (쎌루메)
Description

ECM-based dermocosmetic skincare product line launched by CellArtgen, targeting the aesthetic and skin beauty market.

cellartgen.com
+2 more records
Core offering1 text field

CellArtgen develops and sells organoid-based disease modeling platforms and functional biomaterials for regenerative medicine. Its core offerings include the Regenix decellularized organoid culture material platform covering multiple organ types (liver, lung, heart, intestine, kidney, uterus, muscle, skin, and xenograft) and the ORGANOSCREEN preclinical drug evaluation service that uses organoid disease models for efficacy and safety assessment. The company also extends its ECM biomaterial technology into the consumer skincare market through its Cellumé brand.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Published in Nature Reviews Bioengineering (Impact Factor 37.1)
+4 more records
Product overview1 text field

CellArtgen (CELLARTGEN, CELLARTGEN Inc.) is a regenerative medicine biotech offering a portfolio of products and services centered on its organoid culture technology platform and biomaterial technologies. The core offering is the Regenix® platform, a line of decellularized organoid culture materials branded for specific organ types (Liver, Intestine, Lung, Heart, Kidney, Uterus, Muscle, Skin) available in pre-gel solution and powder forms. Alongside the Regenix® product line, the company provides ORGANOSCREEN, a preclinical drug evaluation service using organoid-based disease models for efficacy and safety assessment. A consumer-facing derma-cosmetic sub-brand, Cellumé (쎌루메), extends the ECM biomaterial technology into the aesthetic skincare market. Regenix® Xenograft supports allogeneic cancer transplantation research.

Product and service3 records
1Regenix
CategoryOrganoid culture materials
2ORGANOSCREEN
CategoryPreclinical evaluation services
3Cellumé
CategoryConsumer skincare
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1오송첨단의료산업진흥재단 (Osong Medical Industry Promotion Foundation)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-30
Description

GMP certification support through Open-Factory facilities including cleanroom, manufacturing space, and quality control support.

cellartgen.com
2성균관대학교 (Sungkyunkwan University)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Lead institution for Ministry of Science and ICT's brain organoid commercialization core technology development project (₩142 billion over 7 years).

cellartgen.com
3넥스트앤바이오, 센트럴바이오 (Next&Bio, CentralBio)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Collaborating partners in brain organoid commercialization project for dementia and Parkinson's precision medicine platform.

cellartgen.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Research affiliation with Yonsei University Life Biotechnology department where CEO Professor Seung Woo Cho serves. Primary research partner for organoid technology development.

5모닛셀 (MonitCell)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-16
Description

Strategic MOU for developing medical biomaterials based on human adipose ECM. Aims to enter beauty, plastic surgery, and advanced regenerative medicine markets.

cellartgen.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-07-01
Description

Commercial license agreement for iPSC-derived organoid manufacturing technology commercialization. iPS Academia Japan manages Shinya Yamanaka's Nobel-winning technology licenses.

7충청도 (Chungbuk Province)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-03-20
Description

Business agreement for global organoid regenerative medicine activation with 14 institutions including provincial government, hospitals, and biotech companies.

cellartgen.com
8강스템 (Kangstem)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-11-02
Description

MOU for diabetes organoid treatment drug development collaboration.

cellartgen.com
9웅비메디텍 (Woongbi Meditech)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-08-11
Description

Joint marketing agreement for organoid culture materials.

cellartgen.com
10멥스젠 (Mepsgen)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-05-24
Description

Collaboration for human tissue chip platform development.

cellartgen.com
11툴젠 (ToolGen)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-09
Description

Joint R&D agreement for gene-corrected stem cell development combining ToolGen's CREAM technology with CellArtGen's functional hydrogel for ischemic disease treatment.

cellartgen.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based organ-on-chip and microphysiological systems company providing in vitro disease models for preclinical drug evaluation. Directly comparable to CellArtgen's ORGANOSCREEN platform, with both targeting pharma preclinical services using human-relevant 3D cellular models.

TypeDirect peer
Description

Swiss 3D organoid and microtissue company providing disease models and preclinical services for pharmaceutical R&D. Directly comparable to CellArtgen's multi-organ organoid product line (liver, lung, heart, etc.) and B2B pharma service model.

TypeBroad incumbent
Description

China-based global CRO/CDMO with extensive preclinical, cell therapy, and organoid-related services. Comparable broad incumbent serving pharma preclinical evaluation, particularly relevant given Asian market overlap.

TypeDirect peer
Description

Canadian supplier of cell culture media, reagents, and organoid tools for life science research. Comparable as a research product catalog player in the organoid ecosystem, with similar B2B distribution model to CellArtgen's Regenix catalog.

TypeBroad incumbent
Description

Global preclinical CRO with broad services including emerging organoid and in vitro capabilities. Represents the broader incumbent landscape CellArtgen competes against for pharma preclinical outsourcing contracts.

TypeDirect peer
Description

Global preclinical CRO with significant organoid and PDX services for oncology and metabolic disease. Direct competitor in organoid-based preclinical drug evaluation, especially relevant as CellArtgen pursues global CRO partnerships for international market access.

7CN Bio
TypeDirect peer
Description

UK organ-on-chip and microphysiological systems company offering single- and multi-organ chips for drug discovery and preclinical testing. CellArtgen partners with Mepsgen (human tissue chip platform), making CN Bio a closely adjacent comparable in human-relevant preclinical platforms.

TypeDirect peer
Description

US-based microphysiological systems company using organ-on-chip technology for preclinical drug testing, particularly in neuromuscular and rare disease. Comparable to CellArtgen's muscle organoid and cardiac organoid services within ORGANOSCREEN.

TypeEmerging player
Description

US-based 3D bioprinting and tissue engineering company focused on therapeutic tissues and preclinical disease models. Comparable adjacent player in regenerative medicine and tissue engineering technology platforms.

TypeRegional player
Description

Korean stem cell therapy company (Cartistem, Neurostem) operating in regenerative medicine. Comparable Korean regional peer in cell-based therapeutics with similar regulatory and market positioning for advanced therapy products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

cellArtgen

Regenerative Medicinecellartgen.com

What cellArtgen does

CellArtgen (주식회사 세라트젠) is a Seoul-based regenerative medicine biotechnology company founded in 2020 as a spin-off from Yonsei University, specializing in the convergence of organoid technology and functional biomaterials. The company develops three core technology platforms: organoid culture and manufacturing technology, organoid advancement/analytical technology (including molecular, electrical, structural, imaging, and AI-based analysis), and engraftable biomaterial technology. Its commercial portfolio centers on the Regenix® platform — decellularized organoid culture materials available across nine organ types (liver, intestine, lung, heart, kidney, uterus, muscle, skin, and xenograft) — and ORGANOSCREEN, a preclinical drug evaluation service using organoid-based disease models for conditions including MASH (liver), IPF (lung), sarcopenia (muscle), and cardiac safety assessment. CellArtgen claims to be Korea's first provider of liver organoid-based MASH and lung organoid-based IPF drug evaluation services.

The company operates a horizontally diversified business model across B2B pharmaceutical services, B2B research product sales, and consumer aesthetics. Revenue is generated through four streams: (1) ORGANOSCREEN preclinical evaluation services sold to domestic and global pharmaceutical companies and CROs, (2) Regenix product sales to research institutions, (3) medical biomaterial products co-developed with partners such as MonetCell for tissue regeneration, and (4) Cellumé, an ECM-based dermocosmetic skincare brand distributed through GS Home Shopping and live commerce channels (including Japan TikTok Shop). The organization has 11-50 employees, holds approximately 90+ domestic and international patents, and reports GMP certification obtained in January 2026 for wound coverage materials. Key academic partnerships include Yonsei University, Sungkyunkwan University, iPS Academia Japan, and the Korea Brain Research Institute, with strategic biotech collaborations including ToolGen, Kangstem, Mepsgen, and Woongbi Meditech.

cellArtgen firmographics

Firmographics
Name
cellArtgen
Legal name
주식회사 세라트젠
Website
https://cellartgen.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

cellArtgen industry classification

Industry
Product category
Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Organoid technology platforms
  • Regenerative medicine solutions
  • Preclinical drug evaluation
  • Biomaterial products
  • Tissue engineering research

Where cellArtgen is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

cellArtgen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Drug Evaluation Services (ORGANOSCREEN): Preclinical evaluation services using organoid-based disease models for pharmaceutical companies. Services include efficacy and safety assessment for drug candidates using liver, lung, muscle, and heart organoids.
  2. Regenix Product Sales: Sale of cell culture materials branded as Regenix for various organoid types (Liver, Intestine, Lung, Heart, Kidney, Uterus, Muscle, Skin, Xenograft).
  3. Biomaterial Products: Medical biomaterials including decellularized ECM products for tissue regeneration and aesthetic applications.
  4. Cellumed Skincare: ECM-based skincare products (Cellumed brand) sold through GS Home Shopping and live commerce channels.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goRegenix product catalog with various organoid types

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

cellArtgen product offering

Product offering

Core offering

CellArtgen develops and sells organoid-based disease modeling platforms and functional biomaterials for regenerative medicine. Its core offerings include the Regenix decellularized organoid culture material platform covering multiple organ types (liver, lung, heart, intestine, kidney, uterus, muscle, skin, and xenograft) and the ORGANOSCREEN preclinical drug evaluation service that uses organoid disease models for efficacy and safety assessment. The company also extends its ECM biomaterial technology into the consumer skincare market through its Cellumé brand.

Product overview

CellArtgen (CELLARTGEN, CELLARTGEN Inc.) is a regenerative medicine biotech offering a portfolio of products and services centered on its organoid culture technology platform and biomaterial technologies. The core offering is the Regenix® platform, a line of decellularized organoid culture materials branded for specific organ types (Liver, Intestine, Lung, Heart, Kidney, Uterus, Muscle, Skin) available in pre-gel solution and powder forms. Alongside the Regenix® product line, the company provides ORGANOSCREEN, a preclinical drug evaluation service using organoid-based disease models for efficacy and safety assessment. A consumer-facing derma-cosmetic sub-brand, Cellumé (쎌루메), extends the ECM biomaterial technology into the aesthetic skincare market. Regenix® Xenograft supports allogeneic cancer transplantation research.

Differentiator

Problem solved

Functional benefit

Brands

  • Cellumé (쎌루메): ECM-based dermocosmetic skincare product line launched by CellArtgen, targeting the aesthetic and skin beauty market.
  • Regenix®
  • ORGANOSCREEN (오가노스크린)

Products and services

  • Regenix
  • ORGANOSCREEN
  • Cellumé

Quantifiable outcome

  • Published in Nature Reviews Bioengineering (Impact Factor 37.1)
  • +4 more outcomes

Companies that use cellArtgen

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

cellArtgen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

cellArtgen partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered minor and core.

  • 오송첨단의료산업진흥재단 (Osong Medical Industry Promotion Foundation)minorStrategic or Co-development Partner · 30 January 2026GMP certification support through Open-Factory facilities including cleanroom, manufacturing space, and quality control support.
  • 성균관대학교 (Sungkyunkwan University)coreStrategic or Co-development Partner · 1 January 2026Lead institution for Ministry of Science and ICT's brain organoid commercialization core technology development project (₩142 billion over 7 years).
  • 넥스트앤바이오, 센트럴바이오 (Next&Bio, CentralBio)minorStrategic or Co-development Partner · 1 January 2026Collaborating partners in brain organoid commercialization project for dementia and Parkinson's precision medicine platform.
  • 연세대학교 (Yonsei University)coreStrategic or Co-development Partner · 1 January 2026Research affiliation with Yonsei University Life Biotechnology department where CEO Professor Seung Woo Cho serves. Primary research partner for organoid technology development.
  • 모닛셀 (MonitCell)coreStrategic or Co-development Partner · 16 July 2024Strategic MOU for developing medical biomaterials based on human adipose ECM. Aims to enter beauty, plastic surgery, and advanced regenerative medicine markets.
  • iPS Academia JapancoreTechnology or Integration · 1 July 2024Commercial license agreement for iPSC-derived organoid manufacturing technology commercialization. iPS Academia Japan manages Shinya Yamanaka's Nobel-winning technology licenses.
  • 충청도 (Chungbuk Province)minorStrategic or Co-development Partner · 20 March 2024Business agreement for global organoid regenerative medicine activation with 14 institutions including provincial government, hospitals, and biotech companies.
  • 강스템 (Kangstem)minorStrategic or Co-development Partner · 2 November 2023MOU for diabetes organoid treatment drug development collaboration.
  • 웅비메디텍 (Woongbi Meditech)minorStrategic or Co-development Partner · 11 August 2023Joint marketing agreement for organoid culture materials.
  • 멥스젠 (Mepsgen)minorStrategic or Co-development Partner · 24 May 2023Collaboration for human tissue chip platform development.
  • 툴젠 (ToolGen)coreStrategic or Co-development Partner · 9 February 2023Joint R&D agreement for gene-corrected stem cell development combining ToolGen's CREAM technology with CellArtGen's functional hydrogel for ischemic disease treatment.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

cellArtgen competitors and assessment

Company assessment

Direct peers

  • Emulate Inc. US-based organ-on-chip and microphysiological systems company providing in vitro disease models for preclinical drug evaluation. Directly comparable to CellArtgen's ORGANOSCREEN platform, with both targeting pharma preclinical services using human-relevant 3D cellular models.
  • InSphero: Swiss 3D organoid and microtissue company providing disease models and preclinical services for pharmaceutical R&D. Directly comparable to CellArtgen's multi-organ organoid product line (liver, lung, heart, etc.) and B2B pharma service model.
  • Stemcell Technologies: Canadian supplier of cell culture media, reagents, and organoid tools for life science research. Comparable as a research product catalog player in the organoid ecosystem, with similar B2B distribution model to CellArtgen's Regenix catalog.
  • Crown Bioscience: Global preclinical CRO with significant organoid and PDX services for oncology and metabolic disease. Direct competitor in organoid-based preclinical drug evaluation, especially relevant as CellArtgen pursues global CRO partnerships for international market access.
  • CN Bio: UK organ-on-chip and microphysiological systems company offering single- and multi-organ chips for drug discovery and preclinical testing. CellArtgen partners with Mepsgen (human tissue chip platform), making CN Bio a closely adjacent comparable in human-relevant preclinical platforms.
  • Hesperos Inc. US-based microphysiological systems company using organ-on-chip technology for preclinical drug testing, particularly in neuromuscular and rare disease. Comparable to CellArtgen's muscle organoid and cardiac organoid services within ORGANOSCREEN.

Broad incumbents

  • WuXi AppTec: China-based global CRO/CDMO with extensive preclinical, cell therapy, and organoid-related services. Comparable broad incumbent serving pharma preclinical evaluation, particularly relevant given Asian market overlap.
  • Charles River Laboratories: Global preclinical CRO with broad services including emerging organoid and in vitro capabilities. Represents the broader incumbent landscape CellArtgen competes against for pharma preclinical outsourcing contracts.

Emerging players

  • Organovo Holdings: US-based 3D bioprinting and tissue engineering company focused on therapeutic tissues and preclinical disease models. Comparable adjacent player in regenerative medicine and tissue engineering technology platforms.

Regional players

  • Medipost: Korean stem cell therapy company (Cartistem, Neurostem) operating in regenerative medicine. Comparable Korean regional peer in cell-based therapeutics with similar regulatory and market positioning for advanced therapy products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

cellArtgen social profiles

Digital presence

cellArtgen compliance and trust

Trust signal

Compliance1 record

cellArtgen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

cellArtgen leadership team

Management profile

Number of profiles

Profiles3 records

cellArtgen funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

cellArtgen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about cellArtgen

What does cellArtgen do?

CellArtgen develops and sells organoid-based disease modeling platforms and functional biomaterials for regenerative medicine. Its core offerings include the Regenix decellularized organoid culture material platform covering multiple organ types (liver, lung, heart, intestine, kidney, uterus, muscle, skin, and xenograft) and the ORGANOSCREEN preclinical drug evaluation service that uses organoid disease models for efficacy and safety assessment. The company also extends its ECM biomaterial technology into the consumer skincare market through its Cellumé brand.

Is cellArtgen a public or private company?

cellArtgen is a private company. It is classified as venture growth investor backed and is currently operating.

When was cellArtgen founded?

cellArtgen was founded in 2020. It employs 1 to 10 people.

Where is cellArtgen based?

cellArtgen is headquartered in Seoul, South Korea, in the Asia region.

How does cellArtgen make money?

Four revenue lines are on record. Drug Evaluation Services (ORGANOSCREEN) is the primary driver. The others are regenix Product Sales, biomaterial Products and cellumed Skincare.

Who are cellArtgen's main competitors?

Direct peers on record are Emulate Inc., InSphero, Stemcell Technologies, Crown Bioscience, CN Bio and Hesperos Inc.. Broad incumbents are WuXi AppTec and Charles River Laboratories. Organovo Holdings is listed as an emerging player. Medipost is listed as a regional player.

Does cellArtgen have an API?

No public API is recorded for cellArtgen.

What industry is cellArtgen in?

cellArtgen's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales